Related Experiment Videos
Preventing warfarin-related bleeding.
1Hospital Medicine Section, Division of General Internal Medicine, and Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA. jeffrey.glasheen@uchsc.edu
Southern Medical Journal
|February 1, 2005
Summary
Warfarin, a common anticoagulant, poses bleeding risks due to its narrow therapeutic index. Careful monitoring and dose adjustments can mitigate these risks, especially during illness or with new medications.
Area of Science:
- Pharmacology
- Clinical Medicine
- Patient Safety
Background:
- Warfarin is a widely prescribed anticoagulant with a narrow therapeutic index.
- Maintaining optimal anticoagulation with warfarin is challenging due to its sensitivity to various factors.
- Bleeding complications are a significant concern in patients treated with warfarin.
Observation:
- Concomitant medication changes and acute illnesses frequently lead to overanticoagulation.
- Supratherapeutic International Normalized Ratios (INRs) indicate excessive anticoagulation.
- Acute bleeding events necessitate immediate intervention.
Findings:
- Effective monitoring strategies, incorporating patient characteristics and therapy details, can reduce warfarin-related bleeding.
- Simple prediction rules aid in identifying patients at higher risk.
- Holding or reducing warfarin dosage is a primary strategy for managing supratherapeutic INRs.
Implications:
- Implementing tailored monitoring and prediction tools can enhance patient safety in warfarin therapy.
- Optimizing warfarin management strategies is crucial for minimizing bleeding events.
- Prompt recognition and management of overanticoagulation are essential for preventing serious adverse outcomes.